首页> 外文期刊>Nature reviews. Urology >Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC
【24h】

Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC

机译:肾癌:替罗罗莫司未能扩大其在mRCC患者中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Mammalian target of rapamycin (mTOR) inhibitor temsirolimus failed to demonstrate superior outcomes to standard therapies for metastatic renal cell carcinoma (mRCC) in two recently published phase III trials.The first trial was set up to investigate whether the combination of temsirolimus and bevacizumab could provide any benefit over interferon-a plus bevacizumab in treatment-naive patients. Both temsirolimus and bevacizumab have modest clinical activity in mRCC but target different pathways (bevacizumab is a monoclonal antibody against vascular endothelial growth factor [VEGF]), making combination therapy a reasonable strategy to explore.
机译:雷帕霉素(mTOR)抑制剂西罗莫司的哺乳动物靶点在两项最近发表的三期转移性肾细胞癌(mRCC)的治疗中均未显示出优于标准疗法的结果。第一个试验旨在研究替西罗莫司和贝伐单抗的组合能否提供治疗效果初治患者比干扰素-a加贝伐单抗的任何获益。替西罗莫司和贝伐单抗在mRCC中均具有适度的临床活性,但靶向不同的途径(贝伐单抗是针对血管内皮生长因子[VEGF]的单克隆抗体),因此联合治疗成为一种合理的研究策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号